- Home
- ABEO vs PVLA Comparison
ABEO vs PVLA Comparison
Compare ABEO & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABEO
- PVLA
- Stock Information
- Founded
- ABEO 1974
- PVLA 2015
- Country
- ABEO United States
- PVLA United States
- Employees
- ABEO N/A
- PVLA N/A
- Industry
- ABEO Biotechnology: Pharmaceutical Preparations
- PVLA Biotechnology: Pharmaceutical Preparations
- Sector
- ABEO Health Care
- PVLA Health Care
- Exchange
- ABEO Nasdaq
- PVLA Nasdaq
- Market Cap
- ABEO 256.9M
- PVLA 253.2M
- IPO Year
- ABEO 1980
- PVLA N/A
- Fundamental
- Price
- ABEO $6.24
- PVLA $24.13
- Analyst Decision
- ABEO Strong Buy
- PVLA Strong Buy
- Analyst Count
- ABEO 5
- PVLA 7
- Target Price
- ABEO $17.80
- PVLA $46.29
- AVG Volume (30 Days)
- ABEO 1.7M
- PVLA 52.4K
- Earning Date
- ABEO 05-15-2025
- PVLA 05-15-2025
- Dividend Yield
- ABEO N/A
- PVLA N/A
- EPS Growth
- ABEO N/A
- PVLA N/A
- EPS
- ABEO N/A
- PVLA N/A
- Revenue
- ABEO N/A
- PVLA N/A
- Revenue This Year
- ABEO N/A
- PVLA N/A
- Revenue Next Year
- ABEO $383.07
- PVLA N/A
- P/E Ratio
- ABEO N/A
- PVLA N/A
- Revenue Growth
- ABEO N/A
- PVLA N/A
- 52 Week Low
- ABEO $3.93
- PVLA $11.17
- 52 Week High
- ABEO $7.32
- PVLA $29.27
- Technical
- Relative Strength Index (RSI)
- ABEO 56.57
- PVLA N/A
- Support Level
- ABEO $5.93
- PVLA N/A
- Resistance Level
- ABEO $7.17
- PVLA N/A
- Average True Range (ATR)
- ABEO 0.44
- PVLA 0.00
- MACD
- ABEO -0.01
- PVLA 0.00
- Stochastic Oscillator
- ABEO 50.00
- PVLA 0.00
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
About PVLA Palvella Therapeutics Inc. Common Stock
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.